Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

750.57 +4.57 (+0.61%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

61 62 Next >

23andMe Angles For A Bigger Regeneron Bid As Ex-CEO Steps Up With A Better Offer ↗

June 05, 2025

Regeneron previously won 23andMe at auction. But now the company wants to reopen bidding with an offer from its former CEO.

Via Investor's Business Daily

Topics Bankruptcy Lawsuit

Why Regeneron Is Falling And Why You Should Avoid It ↗

June 04, 2025

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Via Benzinga

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years ↗

June 03, 2025

Via Benzinga

Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target ↗

June 02, 2025

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce.

Via Benzinga

Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response ↗

June 02, 2025

Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials planned through early 2026.

Via Benzinga

Forecasting The Future: 21 Analyst Projections For Regeneron Pharmaceuticals ↗

May 30, 2025

Via Benzinga

Regeneron Pharmaceuticals Unusual Options Activity For May 30 ↗

May 30, 2025

Via Benzinga

Looking Into Regeneron Pharmaceuticals's Recent Short Interest ↗

May 30, 2025

Via Benzinga

Regeneron To Buy Licensing Rights For China-Developed Investigational Obesity Drug For $2B: Retail Sees Stock Hitting $500 ↗

June 02, 2025

Separately, Regeneron on Monday also announced positive interim data from its ongoing Phase 2 trial investigating novel combinations of semaglutide and Trevogrumab with or without garetosmab for the...

Via Stocktwits

Topics Death

The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip ↗

June 02, 2025

Via The Motley Fool

Topics Economy

Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist

June 02, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass

June 02, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Market Monitor News June 02 (Ulta Beauty, ZScaler UP - GAP, Regeneron DOWN) ↗

June 02, 2025

US stocks ended May cautiously after strong monthly gains, as renewed trade tensions with China stirred market uncertainty.

Via Chartmill

Topics World Trade

Temu Parent PDD, Regeneron Pharmaceutical And Burlington Stores Are Among Top 11 Large-Cap Losers Last Week (May 26-May 30): Are The Others In Your Portfolio? ↗

June 01, 2025

11 large-cap stocks with worst performance in last week: SMMT, PDD, REGN, BAH, OKTA, DECK, CPRT, COO, TPL, HPQ, BURL. Mixed results, lowered forecasts.

Via Benzinga

Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May ↗

May 31, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

May 31, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Top S&P500 movers in Friday's session ↗

May 30, 2025

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.

Via Chartmill

Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. ↗

May 30, 2025

Let's have a look at the S&P500 stocks with an unusual volume in today's session.

Via Chartmill

Why Regeneron (REGN) Shares Are Falling Today

May 30, 2025

Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results from its Phase 3 trials for itepekimab, an experimental drug for Chronic...

Via StockStory

Topics Artificial Intelligence

Discover which S&P500 stocks are making waves on Friday. ↗

May 30, 2025

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Friday as we examine the latest happenings in today's session.

Via Chartmill

Unity Stock Jumps On Upgrade While Regeneron, Cooper Companies Tank On Downgrades – Top Wall Street Analyst Calls Today ↗

May 30, 2025

Jefferies upgraded Unity’s stock to ‘Buy’ from ‘Hold’ with a price target hike to $29 from $22.

Via Stocktwits

Topics ETFs Economy Stocks

Friday's session: gap up and gap down stock in the S&P500 index ↗

May 30, 2025

Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Friday. Stay informed about the latest market trends.

Via Chartmill

Traders are paying attention to the gapping stocks in Friday's session. ↗

May 30, 2025

Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

Elastic, Gap, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

May 30, 2025

Via Benzinga

Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure ↗

May 30, 2025

Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.

Via Investor's Business Daily

These S&P500 stocks are moving in today's pre-market session ↗

May 30, 2025

Pre-market stock analysis of S&P500 stocks on 2025-05-30: top gainers and losers in today's session.

Via Chartmill

Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data ↗

May 30, 2025

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal.

Via Benzinga

Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket ↗

May 30, 2025

Via Benzinga

Regeneron Stock Drops On Mixed Results For Smoker’s Lung Treatment ↗

May 30, 2025

Both trials were conducted during the COVID-19 pandemic, a factor the companies said may have influenced the outcomes.

Via Stocktwits

Topics Government Stocks

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

May 30, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

61 62 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Regeneron Pharmaceuticals (NQ:REGN)

All News about Regeneron Pharmaceuticals

Starting at $3.75/week.

Subscribe Today